NCT00067808View on ClinicalTrials.gov

Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS)

PHASE2CompletedINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
Myelodysplastic SyndromeChronic Myelomonocytic Leukemia
Interventions
DRUG

Decitabine

10 mg/m\^2 by vein over 1 hour daily for 10 days

DRUG

Decitabine

20 mg/m2 by vein (IV) over 1 hour daily x 5 days

DRUG

Decitabine

20 mg/m2 subcutaneous (SQ) daily x 5 days

Trial Locations (1)

77030

University of Texas - MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Eisai Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00067808 - Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS) | Biotech Hunter | Biotech Hunter